Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum.

[1]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[2]  R. Wachter,et al.  Left ventricular heart failure and pulmonary hypertension , 2015, European heart journal.

[3]  R. D. de Boer,et al.  Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. , 2015, European heart journal.

[4]  J. Barberà,et al.  Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.

[5]  V. Roger,et al.  Right Ventricular Function in Heart Failure With Preserved Ejection Fraction: A Community-Based Study , 2014, Circulation.

[6]  Grace Lin,et al.  Right heart dysfunction in heart failure with preserved ejection fraction. , 2014, European heart journal.

[7]  J. Grapsa,et al.  Response to Pulmonary Arterial Hypertension Drug Therapies in Patients with Pulmonary Arterial Hypertension and Cardiovascular Risk Factors , 2014, Pulmonary circulation.

[8]  William T. Abraham,et al.  Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction , 2014, Circulation. Heart failure.

[9]  D. Badesch,et al.  [Definitions and diagnosis of pulmonary hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[10]  Akshay S. Desai,et al.  Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction: Findings From the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2014, Circulation. Heart failure.

[11]  R. Speich,et al.  Anticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) , 2013, Circulation.

[12]  Sanjiv J. Shah,et al.  Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: Baseline Findings From the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial , 2014, Circulation. Heart failure.

[13]  F. Martinez,et al.  Pulmonary hypertension due to left heart diseases. , 2013, Journal of the American College of Cardiology.

[14]  S. Rosenkranz,et al.  Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. , 2013, International journal of cardiology.

[15]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[16]  J. Lordan,et al.  Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. , 2012, American journal of respiratory and critical care medicine.

[17]  S. Rosenkranz,et al.  Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension. , 2012, International journal of cardiology.

[18]  V. Roger,et al.  Pulmonary pressures and death in heart failure: a community study. , 2012, Journal of the American College of Cardiology.

[19]  J. Wild,et al.  ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre , 2011, European Respiratory Journal.

[20]  E. Catherwood,et al.  Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. , 2010, The American journal of cardiology.

[21]  R. Arena,et al.  Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study , 2009, Circulation.

[22]  V. Roger,et al.  Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. , 2009, Journal of the American College of Cardiology.

[23]  R. Gerszten,et al.  Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension , 2007 .

[24]  K. Dickstein,et al.  How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. , 2007, European heart journal.

[25]  G. Lewis,et al.  Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure , 2006, Circulation.

[26]  D. DeMets,et al.  Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. , 2005, Journal of cardiac failure.

[27]  Simon Gibbs,et al.  [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. , 2015, Kardiologia polska.

[28]  M. Gatzoulis,et al.  [Updated clinical classification of pulmonary hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[29]  Marvin Kajy.  Anticoagulation and Survival in Pulmonary Arterial Hypertension Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) , 2014 .

[30]  R. Arena,et al.  PDE 5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function , Cardiac Geometry , and Clinical Status in Patients With Stable Systolic Heart Failure , 2011 .